484 related articles for article (PubMed ID: 24232306)
1. Ketamine infusion for sickle cell pain crisis refractory to opioids: a case report and review of literature.
Uprety D; Baber A; Foy M
Ann Hematol; 2014 May; 93(5):769-71. PubMed ID: 24232306
[TBL] [Abstract][Full Text] [Related]
2. The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease.
Tawfic QA; Faris AS; Kausalya R
J Pain Symptom Manage; 2014 Feb; 47(2):334-40. PubMed ID: 23856095
[TBL] [Abstract][Full Text] [Related]
3. Low-Dose Ketamine Infusion for Adjunct Management during Vaso-occlusive Episodes in Adults with Sickle Cell Disease: A Case Series.
Palm N; Floroff C; Hassig TB; Boylan A; Kanter J
J Pain Palliat Care Pharmacother; 2018 Mar; 32(1):20-26. PubMed ID: 29791238
[TBL] [Abstract][Full Text] [Related]
4. Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Neri CM; Pestieau SR; Darbari DS
Paediatr Anaesth; 2013 Aug; 23(8):684-9. PubMed ID: 23565738
[TBL] [Abstract][Full Text] [Related]
5. Ketamine Infusion for Pain Control in Acute Pediatric Sickle Cell Painful Crises.
Hagedorn JM; Monico EC
Pediatr Emerg Care; 2019 Jan; 35(1):78-79. PubMed ID: 27902670
[TBL] [Abstract][Full Text] [Related]
6. Case report: efficacy and tolerability of ketamine in opioid-refractory cancer pain.
Amin P; Roeland E; Atayee R
J Pain Palliat Care Pharmacother; 2014 Sep; 28(3):233-42. PubMed ID: 25102039
[TBL] [Abstract][Full Text] [Related]
7. Ketamine and lidocaine infusions decrease opioid consumption during vaso-occlusive crisis in adolescents with sickle cell disease.
Puri L; Morgan KJ; Anghelescu DL
Curr Opin Support Palliat Care; 2019 Dec; 13(4):402-407. PubMed ID: 31157658
[TBL] [Abstract][Full Text] [Related]
8. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease.
Nobrega R; Sheehy KA; Lippold C; Rice AL; Finkel JC; Quezado ZMN
Pediatr Res; 2018 Feb; 83(2):445-454. PubMed ID: 28902183
[TBL] [Abstract][Full Text] [Related]
9. Use of low-dose ketamine infusion for pediatric patients with sickle cell disease-related pain: a case series.
Zempsky WT; Loiselle KA; Corsi JM; Hagstrom JN
Clin J Pain; 2010 Feb; 26(2):163-7. PubMed ID: 20090444
[TBL] [Abstract][Full Text] [Related]
10. Tramadol infusion for the pain management in sickle cell disease: a case report.
Erhan E; Inal MT; Aydinok Y; Balkan C; Yegul I
Paediatr Anaesth; 2007 Jan; 17(1):84-6. PubMed ID: 17184440
[TBL] [Abstract][Full Text] [Related]
11. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents.
Finkel JC; Pestieau SR; Quezado ZM
J Pain; 2007 Jun; 8(6):515-21. PubMed ID: 17434801
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Ketamine Infusion for Emergency Department Patients with Severe Pain.
Ahern TL; Herring AA; Miller S; Frazee BW
Pain Med; 2015 Jul; 16(7):1402-9. PubMed ID: 25643741
[TBL] [Abstract][Full Text] [Related]
13. Opioid-sparing effect of intravenous outpatient ketamine infusions appears short-lived in chronic-pain patients with high opioid requirements.
Kapural L; Kapural M; Bensitel T; Sessler DI
Pain Physician; 2010; 13(4):389-94. PubMed ID: 20648208
[TBL] [Abstract][Full Text] [Related]
14. Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma.
Tsui BC; Davies D; Desai S; Malherbe S
J Pediatr Hematol Oncol; 2004 Oct; 26(10):678-80. PubMed ID: 15454842
[TBL] [Abstract][Full Text] [Related]
15. Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial.
van Beers EJ; van Tuijn CF; Nieuwkerk PT; Friederich PW; Vranken JH; Biemond BJ
Am J Hematol; 2007 Nov; 82(11):955-60. PubMed ID: 17617790
[TBL] [Abstract][Full Text] [Related]
16. Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial.
Lubega FA; DeSilva MS; Munube D; Nkwine R; Tumukunde J; Agaba PK; Nabukenya MT; Bulamba F; Luggya TS
Scand J Pain; 2018 Jan; 18(1):19-27. PubMed ID: 29794277
[TBL] [Abstract][Full Text] [Related]
17. Ketamine as an Analgesic Adjunct for Opioid-Induced Hyperalgesia in a Patient With a Sickle Cell Pain Episode.
Martinez MR; Garmon EH; Starling GD; Sheth MA
Ochsner J; 2022; 22(3):281-284. PubMed ID: 36189096
[No Abstract] [Full Text] [Related]
18. Ketamine as an Adjunct to Opioids for Acute Pain in the Emergency Department: A Randomized Controlled Trial.
Bowers KJ; McAllister KB; Ray M; Heitz C
Acad Emerg Med; 2017 Jun; 24(6):676-685. PubMed ID: 28177167
[TBL] [Abstract][Full Text] [Related]
19. Oral ketamine for sickle cell crisis pain refractory to opioids.
Jennings CA; Bobb BT; Noreika DM; Coyne PJ
J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):150-4. PubMed ID: 23692261
[TBL] [Abstract][Full Text] [Related]
20. Improved opioid analgesic effect following opioid dose reduction.
Vorobeychik Y; Chen L; Bush MC; Mao J
Pain Med; 2008 Sep; 9(6):724-7. PubMed ID: 18816332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
